Navigation Links
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
Date:3/13/2008

SEATTLE, March 13 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced financial results for its fourth quarter and year ended Dec. 31, 2007, as well as 2008 financial guidance.

Fourth Quarter and Year 2007 Financial Results

Revenue for the fourth quarter of 2007 was $5.7 million compared with $6.4 million for the fourth quarter of 2006. Revenue for the year ended Dec. 31, 2007, was $20.1 million compared with $36.5 million for the year ended Dec. 31, 2006. Revenue in 2007 was earned through the company's strategic collaboration with Wyeth Pharmaceuticals and consisted of collaborative research funding and amortization of the upfront fee of $40 million received in January 2006. The three-month and 12-month decreases were due to reduced reimbursement revenue from the Wyeth collaboration as a result of the successful transfer of manufacturing activities for TRU-015 from Trubion to Wyeth during 2007, and decreased revenue from the recognition of the $40 million upfront fee from Wyeth due to a change in the estimated research and development period. These decreases were partially offset by an increase in reimbursable clinical costs related to Trubion's Phase IIb clinical trial for TRU-015 completed in July 2007. The 12-month decrease was also due to decreased milestone revenue in 2007 compared with 2006.

Total operating expenses for the fourth quarter of 2007 were $11.4 million compared with $12.2 million for the fourth quarter of 2006. Total operating expenses for the year ended Dec. 31, 2007, were $47.3 million compared with $42.8 million for the year ended Dec. 31, 2006. The three-month decrease was primarily due to a decrease in outside manufacturing costs for TRU-015 due to the succes
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
2. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
3. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
4. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Calif. , Nov. 24, 2014   Veracyte, Inc. ... Bonnie H. Anderson , president and chief executive officer, will ... 26 th Annual Healthcare Conference on Tuesday, December 2, ... . The live audio webcast and subsequent ... http://investor.veracyte.com . Please connect to the website at least 15 ...
(Date:11/24/2014)... 2014  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden Corporation ... the United States District Court for the Northern ... On November 21, 2014 the Markman ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Prominent ... investors will gather on December 3rd at Genetic ... Conferences series. GeneticRx will take place at the ... School and will discuss the present and future ... exon skipping, and gene editing—as well as the ...
(Date:11/22/2014)... Rapids, MI (PRWEB) November 22, 2014 ... opportunity to simulate the proper management of life-like ... and test lung devices . Grand Rapids-based, Michigan ... plans to donate two of the respiratory simulation ... to $15,000 each. Grand Valley and Muskegon Community ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... JOLLA, Calif., Feb. 11 TorreyPines Therapeutics, Inc. ... oral administration of NGX426, an AMPA/kainate-type glutamate receptor ... and female subjects when dosed once daily for ... I trial demonstrating the safety and tolerability of ...
... 11 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... and commercialization of novel drugs in the therapeutic,areas of ... for the fourth quarter and full year ended December ... http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO ) , The net ...
... 2009A team of Los Alamos researchers led by Victor ... multiple electronsis a real phenomenon in tiny semiconductor crystals ... that mimic carrier multiplication. The research, explained in a ... shows the possibility of solar cells that create more ...
Cached Biology Technology:First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 2Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 3Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 4Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 5Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 6Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 7Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 8Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 9Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 10Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 11Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results 12Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
(Date:11/5/2014)... show great diversity in their ability to identify scents ... differ in their perceptual evaluation of odors, with women ... , Sex differences in olfactory detection may play ... connected to one,s perception of smell, which is naturally ... superiority has been suggested to be cognitive or emotional, ...
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... NeuralIQ, a developer of,cyber intelligence tools for information ... team, headed by the appointment of,Donnie Blanks as ... President of Sales and strategy for Perot,Systems, government ... the,company continues to advance its industry presence and ...
... Pa. -- A little known fungus tucked away in ... munch through the hardest of woods according to a ... could lead to innovative methods of controlling the invasive ... down plant biomass for generating biofuels. Microbes in ...
... Atlantic Ocean shows that hot, dry air associated with ... contributor to the quieter-than-expected 2007 hurricane season. Factors ... in a season, including El Nio, sea surface temperatures, ... [identify what agency made these forecasts; otherwise it might ...
Cached Biology News:NeuralIQ Expands Global Leadership Team, Names Donnie Blanks CEO 2NeuralIQ Expands Global Leadership Team, Names Donnie Blanks CEO 3Novel fungus helps beetles to digest hard wood 2Novel fungus helps beetles to digest hard wood 32007 hurricane forecasts took blow from winds and Saharan dry, dusty air 22007 hurricane forecasts took blow from winds and Saharan dry, dusty air 3
...
... PGE1-d4 contains 4 deuterium atoms at ... It is intended for use as an ... by GC- or LC-mass spectrometry. PGE1 is ... (DGLA), but it is virtually undetectable in ...
Direct ELISA Assay Diluent, 10 L...
... ZMD.474. Immunogen: Synthetic peptide derived ... mouse junctophilin-3. Specificity: Specific for ... protein. Reactivity: Mouse (positive controls: ... and heart tissues). Applications: Western ...
Biology Products: